Inogen (INGN) Net Income towards Common Stockholders (2013 - 2026)
Inogen's (INGN) quarterly Net Income towards Common Stockholders came in at -$8.3 million in Q1 2026, down 31.39% year-on-year from -$12.1 million in Q1 2025, and down 199.44% on a QoQ basis from $8.3 million in Q4 2025.
Inogen (INGN) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$8.3 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 31.39% year-over-year to -$8.3 million in Q1 2026; TTM through Mar 2026 was -$10.7 million, a 49.95% increase from a year earlier, with the FY2025 full-year figure at -$8.7 million, up 70.33% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$8.3 million, down from $8.3 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for INGN reached as high as $72.5 million in Q4 2023 and fell as low as -$55.8 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$7.8 million across 5 years, with a median of -$6.3 million in 2025.
- Across the five-year window, Net Income towards Common Stockholders slumped 1314.18% in 2022 and soared 342.69% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$55.8 million in 2022, then soared by 229.8% to $72.5 million in 2023, then tumbled by 104.74% to -$3.4 million in 2024, then surged by 342.69% to $8.3 million in 2025, then slumped by 199.44% to -$8.3 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$8.3 million in Q1 2026, $8.3 million in Q4 2025, and -$5.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Inogen | 173.63 Mn | 63.46 Mn | 37.86 Mn | -8.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.29 Mn |
| Dec 31, 2025 | 8.33 Mn |
| Sep 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | -4.76 Mn |
| Mar 31, 2025 | -6.31 Mn |
| Dec 31, 2024 | -3.43 Mn |
| Sep 30, 2024 | -5.96 Mn |
| Jun 30, 2024 | -5.59 Mn |
| Mar 31, 2024 | -14.58 Mn |
| Dec 31, 2023 | 72.46 Mn |
| Sep 30, 2023 | -45.71 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Mar 31, 2023 | -20.35 Mn |
| Dec 31, 2022 | -55.83 Mn |
| Sep 30, 2022 | -9.51 Mn |
| Jun 30, 2022 | -2.84 Mn |
| Mar 31, 2022 | -13.76 Mn |
| Dec 31, 2021 | -22.56 Mn |
| Sep 30, 2021 | 12.28 Mn |
| Jun 30, 2021 | 4.97 Mn |